In lymphomas originating from B cells, the humoral immune response is severely impaired, and targeted therapies directed at B cells, such as CD20 antibodies, BTK inhibitors, and CAR-T cells, may cause B cell depletion and further suppress humoral immunity. Here, BTK is linked to lymphoma.